Cancer screening ‘not elective,’ says president’s cancer panel, as it pushes for better awarenessnews2022-02-03T11:14:24+00:00February 3rd, 2022|Fierce Pharma|
AbbVie’s blockbuster eye drug Restasis under threat as FDA approves Viatris’ copycatnews2022-02-02T20:56:03+00:00February 2nd, 2022|Fierce Pharma|
Humira rings up $20.7B in 2021, but AbbVie still mum on post-biosimilar expectationsnews2022-02-02T16:52:44+00:00February 2nd, 2022|Fierce Pharma|
DHL earmarks $400M to expand its pharma, medical device supply chain network this yearnews2022-02-02T15:44:28+00:00February 2nd, 2022|Fierce Pharma|
Novartis says Leqvio launch will feature a ‘modest initial ramp,’ but blockbuster potential awaitsnews2022-02-02T15:22:41+00:00February 2nd, 2022|Fierce Pharma|
Novo touts diabetes, obesity growth, but Wegovy supply woes remain top of mindnews2022-02-02T14:17:08+00:00February 2nd, 2022|Fierce Pharma|
UPDATED: Novo touts diabetes, obesity growth, but Wegovy supply woes remain top of mindnews2022-02-02T14:17:08+00:00February 2nd, 2022|Fierce Pharma|
Organon gives staff the day off for International Women’s Day to focus on their healthnews2022-02-02T13:59:59+00:00February 2nd, 2022|Fierce Pharma|
Gilead’s COVID-19 antiviral Veklury blew past sales estimates in late 2021 as omicron surged, vaccinations laggednews2022-02-02T12:39:07+00:00February 2nd, 2022|Fierce Pharma|
How did UCB close its $1.9B deal to buy Zogenix and its key epilepsy drug? SEC filing reveals detailsnews2022-02-01T21:53:16+00:00February 1st, 2022|Fierce Pharma|
